Emphasis of Phytoconstituent in the treatment of cancer

Priyanka Nagwanshi; Leena Sahu; Prerana Sahu; Anjali Sahu; Harish Sharma; Gyanesh Sahu

doi:10.5958/0975-4377.2020.00029.4

Research Journal of Pharmaceutical Dosage Forms and Technology

ISSN

0975-4377 (Online)
0975-234X (Print)

Submit Article

Emphasis of Phytoconstituent in the treatment of cancer

Author(s): Priyanka Nagwanshi, Leena Sahu, Prerana Sahu, Anjali Sahu, Harish Sharma, Gyanesh Sahu

Email(s): gyanesh.sahu@rediffmail.com

DOI: 10.5958/0975-4377.2020.00029.4

Address: Priyanka Nagwanshi, Leena Sahu, Prerana Sahu, Anjali Sahu, Harish Sharma, Gyanesh Sahu
Shri Shankracharya Group of Institutions, Faculty of Pharmaceutical Sciences, Junwani, Bhilai.
*Corresponding Author

Published In: Volume - 12, Issue - 3, Year - 2020

View HTML

View PDF

ABSTRACT:
Phytoconstituent that could be useful in cancer cell and in researches dealing with the development of drug molecules for the treatment of cancer Phytoconstituents are chemical compound that occur naturally in plant. Phytoconstituents are gaining popularity as ingredients in cosmetic formulations as they can protect the skin against exogenous and endogenous harmful agents and can help remedy many skin conditions. Advancement in the field of cancer molecular biology has aided researchers to develop various chemo preventive agents which can target cancer cells exclusively. Present review will contribute in promoting more researches leading towards the development of herbal molecules that could be highly beneficial not only in combating this deadly disease but also in providing an eco-friendly safe and efficacious herbal way.

Keywords:

Cite this article:
Priyanka Nagwanshi, Leena Sahu, Prerana Sahu, Anjali Sahu, Harish Sharma, Gyanesh Sahu. Emphasis of Phytoconstituent in the treatment of cancer. Res. J. Pharma. Dosage Forms and Tech.2020; 12(3):169-177. doi: 10.5958/0975-4377.2020.00029.4

Cite(Electronic):
Priyanka Nagwanshi, Leena Sahu, Prerana Sahu, Anjali Sahu, Harish Sharma, Gyanesh Sahu. Emphasis of Phytoconstituent in the treatment of cancer. Res. J. Pharma. Dosage Forms and Tech.2020; 12(3):169-177. doi: 10.5958/0975-4377.2020.00029.4 Available on: https://rjpdft.com/AbstractView.aspx?PID=2020-12-3-6

REFERENCES:

1. Sharma V, Gupta M, Chauhan DN, Chauhan NS, Goyal RK, Shah K. Novel Drug Delivery Systems for Phytoconstituents: Current and Future Prospects. Novel Drug Delivery Systems for Phytoconstituents. 2019 Jul 23:

2. Tamilselvi N, Krishnamoorthy P, Dhamotharan R, Arumugam P, Sagadevan E. Analysis of total phenols, total tannins and screening of phytocomponents in Indigofera aspalathoides (Shivanar Vembu) Vahl EX DC. Journal of Chemical and Pharmaceutical Research. 2012;4(6):3259-62.

3. Csupor D, Wenzig EM, Zupkó I, Wölkart K, Hohmann J, Bauer R. Qualitative and quantitative analysis of aconitine-type and lipo-alkaloids of Aconitum carmichaelii roots. Journal of Chromatography A. 2009 Mar 13;1216(11):2079-86.

4. Chan C, Zheng S, Zhou B, Guo J, Heid RM, Wright BJ, Danishefsky SJ. The solution to a deep stereochemical conundrum: Studies toward the tetrahydroisoquinoline alkaloids. Angewandte Chemie International Edition. 2006 Mar 6;45(11):1749-54.

5. Wolfenden R, Lu X, Young G. Spontaneous hydrolysis of glycosides. Journal of the American Chemical Society. 1998 Jul 15;120(27):6814-5.

6. Varma N. Phytoconstituents and their mode of extractions: An overview. Res. J. Chem. Environ. Sci. 2016;4(2):8-15.

7. Singh JP, Selvendrian K, Banu SM, Padmavathi R and Salethisekaran D: Protective role of Apigenin on the status of lipid peroxidation and antioxidant defense against heptocarcinogenesis in Wister albino rats. Phytomedicine 2014; 11: 309-314.

8. Yin F, Giuliano AE, Law RE and Van Harle AJ: Apigenin inhibit growth and induces G21M arrest by modulating cyclin-CDK regulators and ERK MAP kinase activation in breast carcinoma cells. Anticancer Res 2011; 21: 413-420.

9. Patel D, Shukla S and Gupta S: Apigenin and cancer chemoprevention: progress, potential and promise (Review). Int J Onco 2007; 30: 233-245.

10. Lin JK, Chen YC, Husang YT and Lin-Shian SY: J: Suppression of protein kinease C and nuclear oncogene expression as possible molecular mechanism of cancer chemoprevention by apigenin and curcumin. Cell Biochem 1997; (Suppl)28-29: 39-48.

11. Choi EJ and Kin GW: 5-Fluorouracil combined with apigenin enhances anticancer activity through induction of apoptosis in human breast cancer MDA-MB-453 cells. Oncology Reports 2009; 22: 1533-1537.

12. Ammon HPT and Wahl MA: Pharmacology of Curcuma longa. Planta Med 1991; 57: 1-7

13. Vopel G, Gaisbaver M and Winker W: Phytotherapie in der Prexis: Deutscher Arzte-verlay 1990; 74.

14. Chen HW and Huang HC: Effect of curcumin on cell cycle progression and apoptosis in vascular smooth cells. Br J Pharma col 1998; 124: 1029-1040.

15. Martin-Cordero C, Loper-Lazaro M, Galvez M and Ayuso MJ: Curcumin as a DNA topoisomerase II poison. J Enzyme Inhib. Med Chem 2003; 18: 505-509.

16. Khar A, Ali AM, Pardhasaradhi BV, Varalakshmi CH, Anjum R and Kumari AL: Induction of stress response renders human tumor cell lines resistant to curcumin mediated apoptosis: role of reactive oxygen intermediates. Cell Stress Chaperones 2001; 6: 368-376.

17. Chattopadhyay I, Biswas K, Bandyopadhyay U and Banerjee RK: Turmeric and Curcumin: Biological actions and medicinal applications. Current Science 2004; 87(1): 44-53.

18. Broadbent TA and Broadbent HS: The chemistry and pharmacology of indole-3-carbinol (indole-3-methanol) and 3-(methoxymethyl) indole [part II]. Curr Med Chem 1998; 5: 469-491.

19. Hong C, Firestone GL and Bjeldanes LF: BCl-2 family –mediated apoptotic effects of 3, 3’-diindelymethane (DIM) in human breast cancer cells. Biochem Pharmacol 2002; 63: 1085-1097.

20. Bonnesan C, Eggleston IM and Hayes JD: Dietary indoles and isothiocynates that are generated from cruciferous vegetables can both stimulate apoptosis and confer protection against DNA damage in human colon cell lines. Cancer Res 2001; 61: 6120-6130.

21. Chinni SR, Li Y, Upadhyay S, Koppolu PK and Sarkar FH: Indole -3- carbinol (I3C) induced cell growth inhibition, G1 cell cycle arrest and apoptosis in prostate cancer cells. Oncogene 2001; 20: 2927-2936.

22. Aggarwal BB and Ichikawa H: Molecular Targets and Anticancer Potential of Indole-3-carbinol and its derivative. Cell Cycle 2005; 4(9): 1201-1215.

23. Arai Y, Wantnable S, Kimira M, Shimoi K, Mochizuki R and Kinae N: Dietary intakes of flavanols, flavones and isoflavones by Japanese woman and inverse correlation between quercetin intake and plasma LDL cholesterol concentration. Nutr 2000; 130: 2243-2250.

24. Higa S, Hirano T and Kotani MJ: Allergy Fisetin a flavanol inhibits TH2-type cytokine production by activated human basophils. Clin Immunol 2003; 111: 1299-1306.

25. Khan N, Afaq F, Sayed DN and Mukhtal H: Fisetin, a novel dietary flavonoid, causes apoptosis and cell cycle arrest in human prostate cancer LMCaP cells. Carcinogenesis 2008; 29: 1049-1056.

26. Pei-Ming Y, Ho-heing T, Chin-ween P, Wen-shu C and Shu-Jun C: Dietary flavonoid fisetin targets caspase-3-deficient human breast cancer MCF-7 cells by induction of caspase-7- associated apoptosis and inhibition of autophagy. International Journal of Oncology 2012; 40: 469-478.

27. Nair MK, Varghese C, Swaminathan R. Cancer: Current scenario, intervention strategies and projections for 2015. NCHM Background papers-Burden of Disease in India. 2005:219-5.

28. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA: a cancer journal for clinicians. 2019 Jan;69(1):7-34.

29. Singh S, Sharma B, Kanwar SS, Kumar A. Lead phytochemicals for anticancer drug development. Frontiers in Plant Science. 2016 Nov 8;7: 1667.

30. Singh S, Sharma B, Kanwar SS, Kumar A. Lead phytochemicals for anticancer drug development. Frontiers in Plant Science. 2016 Nov 8;7: 1667.

31. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA: A Cancer Journal for Clinicians. 2007 Jan;57(1):43-66.

32. Lee JW, Soung YH, Kim SY, Lee HW, Park WS, Nam SW, Kim SH, Lee JY, Yoo NJ, Lee SH. PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. Oncogene. 2005 Feb;24(8):1477.

33. Enzinger FM. Epithelioid sarcoma. A sarcoma simulating a granuloma or a carcinoma. Cancer. 1970 Nov;26(5):1029-41.

34. Miller AJ, Mihm Jr MC. Melanoma. New England Journal of Medicine. 2006 Jul 6;355(1):51-65

35. Gundrum JD, Mathiason MA, Moore DB, Go RS. Primary testicular diffuse large B-cell lymphoma: a population-based study on the incidence, natural history, and survival comparison with primary nodal counterpart before and after the introduction of rituximab. Journal of Clinical Oncology. 2009 Sep 21;27(31):5227-32.

36. Saraf S, Kaur CD. Phytoconstituents as photoprotective novel cosmetic formulations. Pharmacognosy reviews. 2010 Jan;4(7):1.

37. Torre LA, Siegel RL, Jemal A. Lung cancer statistics. Lung cancer and Personalized Medicine. 2016:1-9.

38. Mottet N, Bellmunt J, Briers E, Bolla M, Bourke L, Cornford P, De Santis M, Henry AM, Joniau S, Lam TB, Mason MD. EAU-ESTRO-ESUR-SIOG Guidelines on.

39. Siegel R, DeSantis C, Jemal A. Colorectal cancer statistics, 2014. CA: A Cancer Journal for Clinicians. 2014 Mar;64(2):104-17.

40. Arnold M, Moore SP, Hassler S, Ellison-Loschmann L, Forman D, Bray F. The burden of stomach cancer in indigenous populations: a systematic review and global assessment. Gut. 2014 Jan 1;63(1):64-71.

41. Brenner H, Rothenbacher D, Arndt V. Epidemiology of stomach cancer. Cancer Epidemiology. 2009:467-77.

42. DeSantis CE, Fedewa SA, Goding Sauer A, Kramer JL, Smith RA, Jemal A. Breast cancer statistics, 2015: Convergence of incidence rates between black and white women. CA: A Cancer journal For Clinicians. 2016 Jan;66(1):31-42.

43. Key TJ, Verkasalo PK, Banks E. Epidemiology of breast cancer. The Lancet Oncology. 2001 Mar 1;2(3):133-40.

44. Mortazavi S, Zali M, Raoufi M, Nadji M, Kowsarian P, Nowroozi A. The prevalence of human papillomavirus in cervical cancer in Iran. Asian Pac J Cancer Prev. 2002;3(1):69-72.

45. Bernstein C, Prasad AR, Nfonsam V, Bernstein H. DNA damage, DNA repair and cancer. New Research Directions in DNA Repair. 2013 May 22.

46. Miele E, Spinelli GP, Miele E, Tomao F, Tomao S. Albumin-bound formulation of paclitaxel (Abraxane® ABI-007) in the treatment of breast cancer. International Journal of Nanomedicine. 2009;4:99.

47. Keizer HG, Pinedo HM, Schuurhuis GJ, Joenje H. Doxorubicin (adriamycin): a critical review of free radical-dependent mechanisms of cytotoxicity. Pharmacology & Therapeutics. 1990 Jan 1;47(2):219-31.

48. Marani TM, Trich MB, Armstrong KS, Ness PM, Smith J, Minniti C, Sandler SG. Carboplatin‐induced immune hemolytic anemia. Transfusion. 1996 Nov 12;36(11‐12):1016-8.

49. Desprez JD, Kiehn CL. The effects of cytoxan (cyclophosphamide) on wound healing. Plastic and Reconstructive Surgery. 1960 Sep 1;26(3):301-8.

50. Dzięgiel P, Suder E, Surowiak P, Jethon Z, Rabczyński J, Januszewska L, Sopel M, Zabel M. Role of exogenous melatonin in reducing the nephrotoxic effect of daunorubicin and doxorubicin in the rat. Journal of Pineal Research. 2002 Sep;33(2):95-100.

51. Lyass O, Uziely B, Ben‐Yosef R, Tzemach D, Heshing NI, Lotem M, Brufman G, Gabizon A. Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma. Cancer: Interdisciplinary International Journal of the American Cancer Society. 2000 Sep 1;89(5):1037-47.

52. Effexor XR. Evidence Supporting Use of Ellence®. AWHONN Lifelines.;7(1).

53. Khan MG. Topic-the novel drug delivery system. World of Pharmacy and Pharmaceutical Science ISSN2278 – 4357.

54. Seidman A, Hudis C, Pierri MK, Shak S, Paton V, Ashby M, Murphy M, Stewart SJ, Keefe D. Cardiac dysfunction in the trastuzumab clinical trials experience. Journal of Clinical Oncology. 2002 Mar 1;20(5):1215-21.

55. Reddy PB, Gupta J, Sushma P. Recent Trends in Smart Drug Delivery. Life Sciences International Research Journal, ISSN.:2347-8691.

56. Pili R, Rosenthal MA, Mainwaring PN, Van Hazel G, Srinivas S, Dreicer R, Goel S, Leach J, Wong S, Clingan P. Phase II study on the addition of ASA404 (vadimezan; 5, 6-dimethylxanthenone-4-acetic acid) to docetaxel in CRMPC. Clinical Cancer Research. 2010 May 15;16(10):2906-14.

57. Scott RC, Crabbe D, Krynska B, Ansari R, Kiani MF. Aiming for the heart: targeted delivery of drugs to diseased cardiac tissue. Expert Opinion on Drug Delivery. 2008 Apr 1;5(4):459-70.

58. Couvreur P, Puisieux F. Nano-and microparticles for the delivery of polypeptides and proteins. Advanced Drug Delivery Reviews. 1993 May 1;10(2-3):141-62.

59. Lasic DD. Doxorubicin in sterically stabilized liposomes. Nature. 1996 Apr; 380(6574):561.

60. Ueyama T, Kawashima S, Sakoda T, Rikitake Y, Ishida T, Kawai M, Yamashita T, Ishido S, Hotta H, Yokoyama M. Requirement of activation of the extracellular signal-regulated kinase cascade in myocardial cell hypertrophy. Journal of Molecular and Cellular Cardiology. 2000 Jun

61. Choi HS, Liu W, Misra P, Tanaka E, Zimmer JP, Ipe BI, Bawendi MG, Frangioni JV. Renal clearance of quantum dots. Nature Biotechnology. 2007 Oct;25(10):1165.1;32(6):947-60.

62. Aliabadi HM, Lavasanifar A. Polymeric micelles for drug delivery. Expert Opinion on Drug Delivery. 2006 Jan 1;3(1):139-62.

63. Kwon GS, Forrest ML. Amphiphilic block copolymer micelles for nanoscale drug delivery. Drug Development Research. 2006 Jan;67(1):15-22.

64. Kataoka K, Matsumoto T, Yokoyama M, Okano T, Sakurai Y, Fukushima S, Okamoto K, Kwon GS. Doxorubicin-loaded poly (ethylene glycol)–poly (β-benzyl-l-aspartate) copolymer micelles: their Pharmaceutical Characteristics and Biological Significance. Journal of Controlled Release.

65. Ng KK, Lovell JF, Zheng G. Lipoprotein-inspired nanoparticles for cancer theranostics. Accounts of Chemical Research. 2011 May 10;44(10):1105-13.2000 Feb 14;64(1-3):143-53.

66. 4o. Shahzad MM, Mangala LS, Han HD, Lu C, Bottsford-Miller J, Nishimura M, Mora EM, Lee JW, Stone RL, Pecot CV, Thanapprapasr D. Targeted delivery of small interfering RNA using reconstituted high-density lipoprotein nanoparticles. Neoplasia (New York, NY). 2011 Apr;13(4):309.

67. McConathy WJ, Nair MP, Paranjape S, Mooberry L, Lacko AG. Evaluation of snthetic/reconstituted high-density lipoproteins as delivery vehicles for paclitaxel. Anti-Cancer Drugs. 2008 Feb 1;19(2):183-8.

68. Sabnis N, Nair M, Israel M, McConathy WJ, Lacko AG. Enhanced solubility and functionality of valrubicin (AD-32) against cancer cells upon encapsulation into biocompatible nanoparticles. International journal of nanomedicine. 2012;7:975.

69. Gotto Jr AM, Pownall HJ, Havel RJ. [1] Introduction to the plasma lipoproteins. Methods in Enzymology. 1986 Jan 1;128:3-41.

70. Madaan K, Kumar S, Poonia N, Lather V, Pandita D. Dendrimers in drug delivery and targeting: Drug-dendrimer interactions and toxicity issues. Journal of Pharmacy & Bioallied Sciences. 2014 Jul;6(3):139.

71. Sharma H, Dapurkar VK, Rai G, Sahu GK. Microemulsions for the Topical Administration of 5-Fluorouracil: Preparation and Evaluation. Research Journal of Pharmacy and Technology. 2012 Aug 1;5(8):5.

72. Tripathi S, Sahu UK, Meshram J, Kumari R, Tripathi DK, Alexander A, Sharma H, Sahu GK. Formulation and characterization of Virgin Coconut Oil Emulsion (VCOE) for treatment of Alzheimer's disease. Research Journal of Pharmaceutical Dosage Forms and Technology. 2018 Apr 1;10(2):49-54.

73. Sahu P, Mishra S, Sahu GK, Sharma H, Kaur CD. Formulation and Characterization of Resorcinol Gel. Research Journal of Pharmaceutical Dosage Forms and Technology. 2019 Sep 30;11(3):159-63.

74. Sahu K, Pathak R, Agrawal N, Banjare P, Sharma H, Sahu G. A Review of the Novel Drug Delivery System used in the Treatment of Cancer. Research Journal of Pharmaceutical Dosage Forms and Technology. 2019 Sep 30;11(3):199-205.

75. Mandavi N, Ansari N, Bharti R, Kader N, Sahu GK, Sharma H. Microemulsion: A Potential Novel Drug Delivery System. Research Journal of Pharmaceutical Dosage Forms and Technology. 2018;10(4):266-71.

76. Kader N, Ansari N, Bharti R, Mandavi N, Sahu GK, Jha AK, Sharma H. Novel Approaches for Colloidal Drug Delivery System: Nanoemulsion. Research Journal of Pharmaceutical Dosage Forms and Technology. 2018;10(4):253-8.

77. Sharma H, Sahu U, Kumar G, Kaur CD. A Spectrum of Skin Cancer in Kashmir Valley of India: Kangri Cancer. Journal of Atoms and Molecules. 2019;9(1):1196-205.

78. Yesmin R, Karmakar PC, Ali H, Biswas KK. Membrane stabilizing and thrombolytic activities of methanolic extract of Trichosanthes dioica Roxb. Shoot. Journal of Pharmacognosy and Phytochemistry. 2017;6(5):2500-2.

79. Islam M, Hoshen MA, Ayshasiddeka FI, Yeasmin T. Antimicrobial, membrane stabilizing and thrombolytic activities of ethanolic extract of Curcuma zedoaria Rosc. Rhizome. Journal of Pharmacognosy and Phytochemistry. 2017;6(5):38-41.

80. Sahu P, Mishra S, Sahu GK, Sharma H, Kaur CD. Formulation and Characterization of Resorcinol Peel. Research Journal of Pharmacy and Technology. 2019 Sep 30;11(3):159-63.

Research Journal of Pharmaceutical Dosage Forms and Technology (RJPDFT) is an international, peer-reviewed journal, devoted to pharmaceutical sciences. ...... Read more >>>

RNI: Not Available
DOI: 10.5958/0975-4377